The 10 most recent market catalysts affecting $SGMT, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 24, 2026
Corporate Catalyst
Bearish
Impact 85
Sagimet Biosciences shares are trading lower after Goldman Sachs reinstated the stock with a Sell rating and announced a $7 price target.
The 'Sell' rating from Goldman Sachs, a prominent investment bank, is a major negative catalyst for Sagimet Biosciences. Such a downgrade often triggers a significant sell-off as i…
Sep 24, 2026
Corporate Catalyst
Neutral
Impact 65
Goldman Sachs Reinstates Sell on Sagimet Biosciences, Announces $7 Price Target
Goldman Sachs analyst Andrea Newkirk has reinstated coverage on Sagimet Biosciences (SGMT) with a 'Sell' rating and a $7 price target. This move signals a bearish outlook from a ma…
Sep 9, 2026
Corporate Catalyst
Bullish
Impact 65
Barclays Upgrades Sagimet Biosciences to Overweight, Raises Price Target to $18
Barclays analyst Eliana Merle upgraded Sagimet Biosciences (SGMT) from Equal-Weight to Overweight and more than doubled its price target from $8 to $18. This significant upgrade si…
Sep 9, 2026
Corporate Catalyst
Neutral
Impact 65
Cantor Fitzgerald Initiates Coverage On Sagimet Biosciences with Overweight Rating, Announces Price Target of $10.71
Cantor Fitzgerald analyst Yanni Souroutzidis has initiated coverage on Sagimet Biosciences (SGMT) with an 'Overweight' rating and a price target of $10.71. This event is significan…
Aug 25, 2026
Corporate Catalyst
Neutral
Impact 55
HC Wainwright & Co. Reiterates Buy on Sagimet Biosciences, Maintains $29 Price Target
This 8-K filing discloses that HC Wainwright & Co. analyst Brandon Folkes has reiterated a 'Buy' rating and a $29 price target for Sagimet Biosciences. This action signals continue…
Aug 25, 2026
Corporate Catalyst
Neutral
Impact 55
Sagimet Biosciences’ AURORA Phase 3 Clinical Trial Of FASN Inhibitor Denifanstat In Moderate To Severe Acne Is On Track To Initiate Enrollment In Q4 2026
Sagimet Biosciences announced that its AURORA Phase 3 clinical trial for denifanstat, targeting moderate to severe acne, is on schedule to initiate patient enrollment in Q4 2026. T…
Aug 14, 2026
Corporate Catalyst
Bullish
Impact 75
Sagimet Biosciences shares are trading higher after Citizens raised its price target on the stock from $12 to $29.
The significant jump in Sagimet Biosciences' price target from $12 to $29 by Citizens is a strong bullish signal for the stock. This indicates that the analyst firm sees considerab…
Aug 14, 2026
Corporate Catalyst
Bullish
Impact 55
Citizens Maintains Market Outperform on Sagimet Biosciences, Raises Price Target to $29
Citizens analyst Jonathan Wolleben has maintained a 'Market Outperform' rating on Sagimet Biosciences (SGMT) and substantially raised the price target from $12 to $29. This move in…
Aug 12, 2026
Corporate Catalyst
Bullish
Impact 65
Canaccord Genuity Maintains Buy on Sagimet Biosciences, Raises Price Target to $56
Canaccord Genuity's analyst Edward Nash maintained a 'Buy' rating on Sagimet Biosciences (SGMT) and raised the price target from $49 to $56. This upward revision in the price targe…
Aug 11, 2026
Corporate Catalyst
Bearish
Impact 92
Sagimet Biosciences Q2 EPS $(0.26) Misses $(0.25) Estimate
Sagimet Biosciences (SGMT) announced its Q2 earnings, reporting a loss of $(0.26) per share, which was 4% wider than the analyst consensus estimate of $(0.25). While the loss was a…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.